Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro

Hum Mol Genet. 1999 Apr;8(4):673-82. doi: 10.1093/hmg/8.4.673.

Abstract

Spinocerebellar ataxia type 3, also known as Machado-Joseph disease (SCA3/MJD), is one of at least eight inherited neurodegenerative diseases caused by expansion of a polyglutamine tract in the disease protein. Here we present two lines of evidence implicating the ubiquitin-proteasome pathway in SCA3/MJD pathogenesis. First, studies of both human disease tissue and in vitro models showed redistribution of the 26S proteasome complex into polyglutamine aggregates. In neurons from SCA3/MJD brain, the proteasome localized to intranuclear inclusions containing the mutant protein, ataxin-3. In transfected cells, the proteasome redistributed into inclusions formed by three expanded polyglutamine proteins: a pathologic ataxin-3 fragment, full-length mutant ataxin-3 and an unrelated GFP-polyglutamine fusion protein. Inclusion formation by the full-length mutant ataxin-3 required nuclear localization of the protein and occurred within specific subnuclear structures recently implicated in the regulation of cell death, promyelocytic leukemia antigen oncogenic domains. In a second set of experiments, inhibitors of the proteasome caused a repeat length-dependent increase in aggregate formation, implying that the proteasome plays a direct role in suppressing polyglutamine aggregation in disease. These results support a central role for protein misfolding in the pathogenesis of SCA3/MJD and suggest that modulating proteasome activity is a potential approach to altering the progression of this and other polyglutamine diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcysteine / analogs & derivatives
  • Acetylcysteine / pharmacology
  • Adult
  • Animals
  • Ataxin-3
  • Brain / enzymology
  • Brain / pathology
  • Brain Chemistry
  • COS Cells
  • Cell Line
  • Cell Nucleus / enzymology
  • Cysteine Endopeptidases / drug effects
  • Cysteine Endopeptidases / metabolism*
  • Cysteine Proteinase Inhibitors / pharmacology
  • Dose-Response Relationship, Drug
  • HeLa Cells
  • Humans
  • Immunohistochemistry
  • Inclusion Bodies / enzymology
  • Leukemia, Promyelocytic, Acute
  • Machado-Joseph Disease / enzymology*
  • Machado-Joseph Disease / metabolism
  • Machado-Joseph Disease / pathology
  • Male
  • Multienzyme Complexes / drug effects
  • Multienzyme Complexes / metabolism*
  • Mutation
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / metabolism
  • Nuclear Proteins
  • Oncogene Proteins / chemistry
  • PC12 Cells
  • Peptides / drug effects
  • Peptides / metabolism*
  • Proteasome Endopeptidase Complex
  • Protein Structure, Tertiary
  • Rats
  • Rats, Sprague-Dawley
  • Repressor Proteins

Substances

  • Cysteine Proteinase Inhibitors
  • Multienzyme Complexes
  • Nerve Tissue Proteins
  • Nuclear Proteins
  • Oncogene Proteins
  • Peptides
  • Repressor Proteins
  • lactacystin
  • polyglutamine
  • ATXN3 protein, human
  • Ataxin-3
  • Atxn3 protein, rat
  • Cysteine Endopeptidases
  • Proteasome Endopeptidase Complex
  • Acetylcysteine